ICR acquires Consilium, creating global leader in healthcare communications

  • Consilium to combine with ICR’s US-based healthcare practice, providing clients with seamless integrated support for strategic communications and investor engagement across US, Europe and Asia
  • Combined practice includes more than 100 team members and nearly 200 clients
  • Consilium founders to lead European operations as members of healthcare executive team at ICR
  • Acquisition follows successful long-standing joint venture partnership

 ICR, a leading global strategic communications and advisory firm, today announced it has acquired Consilium Strategic Communications, a leading international strategic healthcare communications and investor relations firm focused on Europe and headquartered in London. The transaction, which follows almost a decade of joint venture collaboration, will combine Consilium with ICR’s US-based healthcare practice, ICR Westwicke, forming a global healthcare strategic and financial communications powerhouse with nearly 200 clients and more than 100 team members across three continents.

Current clients of Consilium will immediately benefit from the full breadth of ICR’s services including: investor relations; capital markets and IPO advisory; investor access; ESG advisory; corporate communications and media relations; crisis and special situations; marketing PR; social media; and branding & design. Consilium will operate under the “ICR Consilium” brand and integrate its teams and activities with ICR’s existing healthcare practice.

Consilium was formed in 2013 by Mary-Jane Elliott, Founder and Managing Partner, along with Amber Fennell, Senior Partner and Co-founder. Over the past 10 years the firm has grown to become the market leader in healthcare strategic communications and IR in Europe. Mary-Jane Elliott will continue to lead the firm from its headquarters in London and both she and Amber Fennell will join the ICR healthcare leadership team, which includes Mark Klausner and Bob East (for Investor Relations), and Terri Clevenger and Michael O’Brien (for Public Relations). The transaction establishes ICR’s first official on-the-ground presence in Europe, broadening its global footprint to now include North America, Asia Pacific and UK/Europe.

Tom Ryan, Founder & CEO of ICR, said: “Consilium has long been recognized as the preeminent healthcare communications and advisory firm across Europe and our years of collaboration have allowed us to learn first-hand what makes them so unique. MJ, Amber and their team have built an incredible business, with a hard-earned reputation for deep sector expertise, highly strategic counsel and outstanding client service. Their business and culture could not align more perfectly with ICR’s and we are thrilled to advance our partnership as a single, unified team.

“We were fortunate to add the Westwicke team to ICR in 2019 and have enjoyed tremendous success since then, growing our healthcare practice nearly three-fold. Combining the Consilium and ICR Westwicke teams allows us to offer truly comprehensive global support to healthcare companies while also extending ICR’s presence into Europe,” Mr. Ryan continued.

Mary-Jane Elliott, Managing Partner at ICR Consilium, said: "Over the past 10 years we have had the great pleasure to build Consilium into Europe's leading independent strategic communications agency for the healthcare sector with the sole purpose of serving our clients globally. I am extremely proud of what we have achieved as a team and thank our clients, colleagues past and present, and fellow advisors for their ongoing trust and support.

"I am excited by our next phase of growth as part of ICR, who are backed by two leading global private equity firms – CDPQ and Investcorp, and what opportunities this offers, particularly in the US, to our clients and colleagues, including offering a broader range of capabilities. We have been joint-venture partners for almost a decade and have a complementary fit in international healthcare PR and IR advisory work. Over the years of working with ICR we have shared many clients and delivered fantastic and seamless benefits, as well as formed strong relationships with the ICR team across the US. Now is the right time to deepen that relationship, which coincides with hopefully the continued re-opening of the capital markets, and we look forward to what we can accomplish together,” Mary-Jane Elliott added.

This transaction creates one of the largest global specialist healthcare communications practices and significantly enhances ICR’s capabilities in Europe, by increasing its practice size in both revenue and headcount and broadening its service offerings. The ICR and Consilium combination will immediately provide existing and new ICR Consilium clients with access to integrated support across ICR’s entire platform of services and the combination creates exciting new growth opportunities for all team members. 

Together, ICR and Consilium bring unmatched depth of expertise in healthcare advisory services across IR and strategic communications and the capabilities to support healthcare companies globally across all subsectors including biopharma, medical technology, diagnostics, healthcare services and information technology, and through all stages of growth from early-stage development, to public offerings, to mature public companies.  The firm’s full range of critical strategic communication and investor relations services enable the combined team to support healthcare businesses and leaders with strategic expertise for gaining investor support, building and managing reputation, executing and communicating capital raising and other transactions, responding to crises, introducing new products, communicating regulatory developments and more.

Consilium's team of more than 45 PR and IR professionals, including former journalists, sell-side analysts, industry communications experts, and financial PR practitioners combines with ICR Westwicke’s more than 70 team members with similar professional backgrounds in healthcare. Consilium adds to ICR’s existing client base and bolsters the firm’s expertise in strategic healthcare communications and investor relations, with deep industry knowledge and an unrivalled network across the US, UK, continental Europe and Asia.

Amber Fennell, Senior Partner, ICR Consilium, added: “The combination of Consilium with ICR creates an unrivalled transatlantic strategic communications practice providing support across all aspects of healthcare corporate communications and financial transactions. ICR has an excellent brand and reputation and is one of the fastest growing communications agencies in the US. Working together we will be able to provide our combined healthcare clients with even more seamless and integrated access to a breadth of PR and IR advisory services, in London, across Europe and in the US.”

 

More news and updates 

Stablepharma secures Innovate UK grant, bridge funding round to launch

This joint Innovate UK grant will advance the clinical development of Stablepharma’s lead candidate, SPVX02, a fridge-free vaccine for the prevention of Tetanus and Diphtheria, validating its safety and efficacy through first-in-human clinical trials.

Broken String Biosciences closes $15 million Series A funding round

Broken String Biosciences (“Broken String”), a genomics company building a technology platform to drive the development of cell and gene therapies that are safer by design,  has closed a $15 million Series A investment round.

CPI launches RNA Centre of Excellence

UK's first RNA therapeutic innovation center opens in Darlington, driving cutting-edge vaccine and therapeutic development.

UK rare disease research landscape mapped for first time

A detailed view of rare disease research in the UK has been captured for the first time in a new report published today. It reveals over £1.1 billion has been invested by Government and charities over a five-year-period.

Life Science Group: A finalist for the Innovate UK KTP Awards 2023

Life Science Group (LSG) proudly announces its selection as a finalist in the Impact and Transformation Award category of the esteemed 2023 Innovate UK Knowledge Transfer Partnership (KTP) Best of the Best Awards.

Advancing early lung cancer diagnosis

Life Science Group are delighted to be part of a consortium, led by Welsh scientists at Aberystwyth University, to develop a novel and potentially disruptive lateral flow device for the detection of early-stage lung cancer.

Accelerating innovation in cell culture solutions through collaborative funding

Life Science Group Ltd (LSG) is excited to announce that its joint application with the Mary Lyon Centre (MLC) at MRC Harwell to the MRC National Mouse Genetics Network (NMGN) Business Engagement Fund has been approved in principle, pending the signature of the relevant agreements.

FDA grants US Orphan Drug Designation to Medannex's MDX-124

Medannex Ltd announced today that its novel therapy, MDX-124, has been granted Orphan Drug Designation by the U.S. Food & Drug Administration (FDA).

AlveoGene launches to develop inhaled gene therapies for rare respiratory disorders

New gene therapy company created and funded by Oxford Science Enterprises, Harrington Discovery Institute and Old College Capital in partnership with six leading scientists from the world-renowned UK Respiratory Gene Therapy Consortium (GTC)

AstraZeneca commits £100 million to advance UK energy efficiency

15-year agreement with Future Biogas will provide 100 GWh of green gas (biomethane) annually, equivalent to meet the heat demands of over 8,000 homes

 

More within